Methocarbamol

Summary

Methocarbamol (CHEMBL1201117) is an approved small molecule (ATC M03BA53) targeting CA1; indicated across 2 conditions including cirrhosis of liver.

At a glance

• Status: Approved (max clinical phase 4)
• Modality: Small molecule
• ATC class: M03BA53 (+2 more)
• Targets: 1 (CA1)
• Indications: 2 conditions
• Clinical trials: 9
• Chemistry: 241.24 Da · C11H15NO5

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL1201117
Name	Methocarbamol
Type	Small molecule
Max phase	4
FDA approved	yes
PubChem CID	4107
ChEBI	CHEBI:77498
ATC	M03BA53, M03BA03, M03BA73
Molecular formula	C11H15NO5
Molecular weight	241.24
InChIKey	GNXFOGHNGIVQEH-UHFFFAOYSA-N

SMILES: COC1=CC=CC=C1OCC(COC(=O)N)O

IUPAC name: [2-hydroxy-3-(2-methoxyphenoxy)propyl] carbamate

ChEBI definition: A carbamate ester that is glycerol in which one of the primary alcohol groups has been converted to its 2-methoxyphenyl ether while the other has been converted to the corresponding carbamate ester.

Also known as: Delaxin, Forbaxin, Methocarbamol, Methocarbamol component of robaxisal, Metocarbamol, Miolaxin, NSC-170960, Neuraxin, Robaxin, Robaxin-750, SID855587, METHOCARBAMOL

Patent coverage: 2,120 distinct patent families (8,216 SureChEMBL compound mentions), from 2 matched compound structure(s). One matched structure accounts for 8,085 (98%) of the total. Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.

Targets

Targets

Primary targets (GtoPdb curated mechanism): the Cancer dependency column is the DepMap CRISPR fitness signal (% of screened cell lines dependent on the target).

Gene	Target	Action	pAffinity	Cancer dependency	UniProt
CA1	carbonic anhydrase 1	Inhibition	7.6	0%	P00915

Broader ChEMBL bioactivity targets: 1 (assay-derived). Sample: Survival motor neuron protein.

Bioactivity

ChEMBL activities: 1 potent at pChembl ≥ 5 of 1 total. Top 30 by potency (10 = 0.1 nM, 6 = 1 µM):

Target	pChembl	Type	Value	Unit	Activity ID
SMN1	6.1	Potency	794.3	nM	CHEMBL_ACT_3885854

Target pathways

Aggregated over 1 target gene(s): CA1.

Top Reactome pathways

12 total, by targets touching each:

Pathway	Targets	Genes
Erythrocytes take up carbon dioxide and release oxygen	1	CA1
Erythrocytes take up oxygen and release carbon dioxide	1	CA1
Cytokine Signaling in Immune system	1	CA1
Metabolism	1	CA1
Reversible hydration of carbon dioxide	1	CA1
O2/CO2 exchange in erythrocytes	1	CA1
Immune System	1	CA1
Transport of small molecules	1	CA1
Interleukin-12 family signaling	1	CA1
Signaling by Interleukins	1	CA1
Gene and protein expression by JAK-STAT signaling after Interleukin-12 stimulation	1	CA1
Interleukin-12 signaling	1	CA1

Dominant GO biological processes

GO term	Targets
response to fructose	1

Indications & clinical

Indications

2 indications (0 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).

Indication	Trial phase	MONDO	EFO
cirrhosis of liver	3	MONDO:0005155	EFO:0001422

1 further indication record had no mapped disease name (EFO/MeSH-only) or were duplicates, and are omitted.

Clinical trials

Total trials: 9.

Phase distribution

Phase	Trials
PHASE4	4
PHASE3	3
Not specified	2

Top trials by phase / activity

NCT	Phase	Status	Title
NCT05076110	PHASE4	RECRUITING	Nonopioid Pain Control Regimen After Arthroscopic Hip Procedures
NCT05388929	PHASE4	ACTIVE_NOT_RECRUITING	Methocarbamol in Ventral and Inguinal HR
NCT02432456	PHASE4	COMPLETED	Ketamine Infusion Therapy for the Management of Acute Pain in Adult Rib Fracture Patients
NCT02665286	PHASE4	COMPLETED	Orphenadrine and Methocarbamol for LBP
NCT02642874	PHASE3	UNKNOWN	Methocarbamol in Treatment of Muscle Cramps in Cirrhotic Patients
NCT02831569	PHASE3	COMPLETED	Japanese IP-TN Trial
NCT05603832	PHASE3	COMPLETED	A Phase 3 Study of F14 for Management of Pain Following Total Knee Replacement
NCT05100017	Not specified	ACTIVE_NOT_RECRUITING	Methocarbamol vs Oxybutynin for Management of Pain and Discomfort S/P Ureteroscopy Procedure
NCT06659965	Not specified	COMPLETED	Intravenous Methocarbamol for Acute Pain After Spine Surgery

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No CPIC/DPWG dosing guideline or drug-level clinical/variant annotations in PharmGKB for this molecule.

Related molecules

Related molecules

Molecules sharing ≥1 of this drug’s curated primary targets, merged from two biobtree sources and ranked by shared-target count, then clinical phase: ChEMBL clinical-stage candidates (development phase ≥2) and PubChem drug-class bioactivity (approved / known drugs acting on the target). Deduplicated by drug name; the drug’s own salt forms are excluded. Note: for a drug with few primary targets a shared-target match can reflect off-target / promiscuous binding rather than the same therapeutic mechanism — the phase ordering surfaces bona-fide therapeutics first.

69 molecules share ≥1 primary target. Top 60 by shared-target count:

Molecule	Source	Status	Shared targets
PAZOPANIB	ChEMBL + PubChem	Phase 4 (approved)	CA1
ACETAMINOPHEN	ChEMBL	Phase 4 (approved)	CA1
ACETAZOLAMIDE	ChEMBL	Phase 4 (approved)	CA1
BORTEZOMIB	ChEMBL	Phase 4 (approved)	CA1
BRINZOLAMIDE	ChEMBL	Phase 4 (approved)	CA1
CELECOXIB	ChEMBL	Phase 4 (approved)	CA1
CHLOROTHIAZIDE	ChEMBL	Phase 4 (approved)	CA1
CHLORTHALIDONE	ChEMBL	Phase 4 (approved)	CA1
COUMARIN	ChEMBL	Phase 4 (approved)	CA1
DICHLORPHENAMIDE	ChEMBL	Phase 4 (approved)	CA1
DIFLUNISAL	ChEMBL	Phase 4 (approved)	CA1
DOBUTAMINE	ChEMBL	Phase 4 (approved)	CA1
DORZOLAMIDE	ChEMBL	Phase 4 (approved)	CA1
ETHOXZOLAMIDE	ChEMBL	Phase 4 (approved)	CA1
FAMOTIDINE	ChEMBL	Phase 4 (approved)	CA1
FUROSEMIDE	ChEMBL	Phase 4 (approved)	CA1
HYDROCHLOROTHIAZIDE	ChEMBL	Phase 4 (approved)	CA1
HYDROQUINONE	ChEMBL	Phase 4 (approved)	CA1
IMATINIB	ChEMBL	Phase 4 (approved)	CA1
INDAPAMIDE	ChEMBL	Phase 4 (approved)	CA1
LACOSAMIDE	ChEMBL	Phase 4 (approved)	CA1
LEVETIRACETAM	ChEMBL	Phase 4 (approved)	CA1
MAFENIDE	ChEMBL	Phase 4 (approved)	CA1
METHAZOLAMIDE	ChEMBL	Phase 4 (approved)	CA1
NILOTINIB	ChEMBL	Phase 4 (approved)	CA1
NITROUS ACID	ChEMBL	Phase 4 (approved)	CA1
PHENOL	ChEMBL	Phase 4 (approved)	CA1
PROPOFOL	ChEMBL	Phase 4 (approved)	CA1
SALICYLIC ACID	ChEMBL	Phase 4 (approved)	CA1
SODIUM	ChEMBL	Phase 4 (approved)	CA1
SULFANILAMIDE	ChEMBL	Phase 4 (approved)	CA1
SULFASALAZINE	ChEMBL	Phase 4 (approved)	CA1
SULFUR	ChEMBL	Phase 4 (approved)	CA1
SULPIRIDE	ChEMBL	Phase 4 (approved)	CA1
SULTHIAME	ChEMBL	Phase 4 (approved)	CA1
TANNIC ACID	ChEMBL	Phase 4 (approved)	CA1
TAVABOROLE	ChEMBL	Phase 4 (approved)	CA1
TOPIRAMATE	ChEMBL	Phase 4 (approved)	CA1
TRICHLORMETHIAZIDE	ChEMBL	Phase 4 (approved)	CA1
TRIENTINE	ChEMBL	Phase 4 (approved)	CA1
VALDECOXIB	ChEMBL	Phase 4 (approved)	CA1
VERALIPRIDE	ChEMBL	Phase 4 (approved)	CA1
ZONISAMIDE	ChEMBL	Phase 4 (approved)	CA1
BICARBONATE	ChEMBL	Phase 3	CA1
CAFFEIC ACID	ChEMBL	Phase 3	CA1
CURCUMIN	ChEMBL	Phase 3	CA1
GUAIACOL	ChEMBL	Phase 3	CA1
P-TOLUENESULFONAMIDE	ChEMBL	Phase 3	CA1
PRITELIVIR	ChEMBL	Phase 3	CA1
QUERCETIN	ChEMBL	Phase 3	CA1
RESVERATROL	ChEMBL	Phase 3	CA1
SACCHARIN	ChEMBL	Phase 3	CA1
SPERMIDINE	ChEMBL	Phase 3	CA1
BENZYLSULFAMIDE	ChEMBL	Phase 2	CA1
CARZENIDE	ChEMBL	Phase 2	CA1
COUMAPHOS	ChEMBL	Phase 2	CA1
DITIOCARB	ChEMBL	Phase 2	CA1
ELLAGIC ACID	ChEMBL	Phase 2	CA1
FLAVONE	ChEMBL	Phase 2	CA1
GALLIC ACID	ChEMBL	Phase 2	CA1